Wondfo Receives Health Canada Approval for WELL life™ COVID-19 / Influenza A&B Home Test

Enabling Rapid At-Home Identification and Differentiation of Respiratory Infections

Wondfo, a wholly owned subsidiary of Wondfo Biotech, is pleased to announce that Health Canada has granted approval for Canadian distribution of the WELL life™ COVID-19 / Influenza A&B Home Test.

The WELL life™ COVID-19 / Influenza A&B Home Test is the first and only combined Class IV device approved for use by Health Canada.

The test is designed for rapid, over-the-counter (home) use, combining qualitative detection and differentiation of influenza A, influenza B, and SARS-CoV-2 infections within four days of symptom onset. At home testing using anterior nasal samples reduces the need for doctor's office visits and prevents virus spread, while allowing physicians to provide targeted treatment.

"Health Canada's approval of our WELL life™ COVID-19 / Influenza A&B Home Test demonstrates our continued dedication to the development of rapid and innovative home healthcare solutions."
— Brian Drake, Vice President of Sales and Downstream Marketing at Wondfo

Wondfo is a leading international manufacturer of point-of-care tests providing rapid diagnostic and chronic disease management solutions in four major categories including Toxicology Testing, Infectious Disease, Women’s Reproductive Health, and Veterinary Diagnostics. Wondfo operates a substantive Canadian distribution center as well as boasting North American manufacturing and R&D facilities. This commitment to local manufacturing and distribution enhances Wondfo's ability to readily and reliably supply products to the Canadian market.

To learn more about the WELL life™ COVID-19 / Influenza A&B Home Test please visit **wondfousa.com.**

Media Contact:
Brian Drake
Vice President, Sales and Downstream Marketing
brian.d@wondfousa.com